Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
Ronald V. Lacro, Harry C. Dietz, Lisa M. Wruck, Timothy J. Bradley, Steven D. Colan, Richard B. Devereux, Gloria L. Klein, Jennifer S. Li, L. LuAnn Minich, Stephen M. Paridon, Gail D. Pearson, Beth F. Printz, Reed E. Pyeritz, Elizabeth Radojewski, Mary J. Roman, J. Philip Saul, Mario P. Stylianou, Lynn Mahony
Dive into the research topics of 'Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome'. Together they form a unique fingerprint.